Vagal Afferent Mediates the Anorectic Effect of Peripheral Secretin by Sekar, R et al.
Title Vagal Afferent Mediates the Anorectic Effect of PeripheralSecretin
Author(s) Chu, JYS; Cheng, YY; Sekar, R; Chow, BKC
Citation PLoS One, 2013, v. 8, p. e64859
Issued Date 2013
URL http://hdl.handle.net/10722/190368
Rights Creative Commons: Attribution 3.0 Hong Kong License
Vagal Afferent Mediates the Anorectic Effect of
Peripheral Secretin
Jessica Y. S. Chu., Carrie Y. Y. Cheng., Revathi Sekar, Billy K. C. Chow*
School of Biological Sciences, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
Abstract
Secretin (SCT) is a classical peptide hormone that is synthesized and released from the gastrointestinal tract after a meal. We
have previously shown that it acts both as a central and peripheral anorectic peptide, and that its central effect is mediated
via melanocortin system. As peripheral satiety signals from the gastrointestinal tract can be sent to the brain via the vagal
afferent or by crossing the blood-brain barrier (BBB), we therefore sought to investigate the pathway by which peripheral
SCT reduces appetite in this study. It is found that bilateral subdiaphragmatic vagotomy and treatment of capsaicin, an
excitotoxin for primary afferent neurons, could both block the anorectic effect of peripherally injected SCT. These
treatments are found to be capable of blunting i.p. SCT-induced Fos activation in pro-opiomelanocortin (POMC) neurons
within the hypothalamic Arcuate Nucleus (Arc). Moreover, we have also found that bilateral midbrain transaction could
block feeding reduction by peripheral SCT. Taken together, we conclude that the satiety signals of peripheral SCT released
from the gastrointestinal tract are sent via the vagus nerves to the brainstem and subsequently Arc, where it controls central
expression of other regulatory peptides to regulate food intake.
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Introduction
SCT, a 27-amino acid peptide hormone primarily produced
from duodenal S cells, belongs to the vasoactive intestinal
polypeptide (VIP)/secretin/glucagon/growth hormone-releasing
hormone (GHRH) peptide family [1]. The physiological role of
this gastrointestinal hormone is to provide an optimum condition
for food digestion in the intestine by regulating gastric secretion
and emptying [2–5] and stimulating the release of bicarbonate-
enriched fluid from the pancreas [6,7] and bile from the liver [8,9].
Plasma SCT levels increase postprandially [10–13], suggesting
that SCT may function as a peripheral satiety signals. We have
recently identified SCT and its receptor expression in the
hypothalamus [14,15], which is a region implicated in energy
homeostasis, and that SCT is an anorectic peptide, which inhibits
food intake in mice when administered peripherally or centrally
[16]. SCT could also activate POMC neurons by augmenting
POMC mRNA levels in the Arc, suggesting a role for Arc POMC
in mediating the anorectic action of SCT.
Vagal afferent fibres of the vagus nerve are the major
neuroanatomical structure connecting the alimentary tract to the
nucleus of the solitary tract (NTS) in the hindbrain. Gut hormones
transmit satiety signals to the brain via the vagal afferent pathways,
bloodstream or both. SCT is capable of crossing the BBB and
reach the brain by transmembrane diffusion via a non-saturable
mechanism [17] and SCTR transcript and protein are detected in
the Arc and PVN [16], suggesting that circulating SCT may
directly activate neurons in hypothalamic centres for appetite
control. However, SCTR was found in vagal afferents, and also
subdiaphragmatic vagotomy was able to block i.p.-SCT-induced
Fos expression in the rat brain [18], suggesting an alternative
pathway that peripheral SCT may communicate with the central
feeding centre via vagus nerve. In this study, we investigated the
potential role of vagus nerve in relaying SCT-induced signal for
satiety to the brain. We studied the effect of peripherally
administered SCT on food intake in mice with subdiaphragmatic
vagotomy and capsaicin, a specific afferent neurotoxin, treatment.
We also examined the effect of these procedures on SCT-induced
Fos expression in POMC neurons in the Arc.
Materials and Methods
Animal Handling
The procedures of animal care and handling were in
accordance with the protocol approved by the Committee on
the Use of Live Animals in Teaching and Research (CULATR) of
the University of Hong Kong. All experiments were carried out
using wild-type adult male mice (20–25 g), which were kept in a
temperature-controlled room with a 12-h light/dark cycle. Mice
were fed ad libitum with standard rodent chow (no. 5010, Test
Diet, IN) and water, unless otherwise stated, and for those that
were subjected to surgical experiment, subcutaneous burenorphine
(0.1 mg/kg, q12 h) and amoxicillin (100 mg/kg, 12–24 hourly)
were administered for the 5 days of recovery time as analgesia and
anti-flammatory drug.
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Subdiaphragmatic Vagotomy
Mice were anesthetized and surgery was conducted in aseptic
conditions. The stomach and lower oesophagus were exposed after
an upper midline laparotomy. The stomach was gently retracted,
and the anterior and posterior vagal trunks were exposed and
transected. In sham-operated mice, a similar abdominal incision
was made; the vagal trunks were identified but not transected. All
operated mice were allowed to recover 2 weeks prior to ICV
experimentation.
Capsaicin Treatment
Mice were treated with increasing doses of capsaicin in one
daily intra-peritoneal (i.p.) injections over 3 consecutive days
(8 mg/kg, 20 mg/kg and 30 mg/kg). Capsaicin was dissolved in
10% ethanol and 10% Tween 80 in 0.9% sterile saline. To
counteract respiratory impairment associated with capsaicin
administration, mice were pretreated with atropine (0.2 mg/kg),
terbutaline (0.2 mg/kg), and aminophylline (20 mg/kg). Control
mice underwent the same experimental procedure described
above, but were injected with vehicle without capsaicin. Feeding
studies were performed 2 weeks after the last capsaicin injection.
To check the effectiveness of capsaicin pretreatment, the
abdominal constrictions in response to i.p injection of 0.01%
acetic acid were evaluated. Mice that didn’t display abdominal
constrictions to the injection had the vagal afferent successfully
lesioned.
Bilateral Midbrain Transection
Bilateral midbrain transection was performed at a site rostral to
the NTS to investigate whether the ascending efferents of the NTS
are necessary in mediating i.p. SCT effects on food intake. Briefly,
the head of the mouse was fixed in a stereotaxic instrument. A steel
knife (1 mm wide) was lowered into the brain in a coronal plane,
bilaterally 0.5 mm from the midline, 3.5 mm caudal to the
bregma, and 4.5 mm ventral to the dura. For sham operation, the
skull was exposed and two holes were drilled on both sides of the
midline, while the brain was left intact. After the feeding test, the
brains were removed and the exact location of the lesion was
verified histologically.
Intracerebroventricular (i.c.v.) Cannulation and Injection
Mice were implanted with a permanent 11-mm-long, 21-gauge
stainless steel cannula projecting to the lateral ventricle, according
to the co-ordinates of Paxinos and Franklin (2001). (Coordinates
relative to bregma were as follows: i.c.v, 1.00 mm lateral, 0.5 mm
posterior, and 2.0 mm ventral). Cannula placement was confirmed
by injection of a dye and injections were done using PE-10 tubing
attached to an injector and a 10-ml Hamilton syringe. All animals
were allowed to recover from surgery for a minimum of 5–7 days,
then artificial cerebrospinal fluid (aCSF; prepared according to
Alzet protocol, 5 ml) and SCT (454 ng/5 ml; 60677; AnaSpec, San
Jose, CA) were injected into the lateral ventricle.
Feeding Studies
Experimental mice (sham-operated, vagotomized and capsaicin-
treated) were fasted for 18 h before study. During the early light
phase (10:00), mice were injected with SCT (i.c.v.: 0.15 nmol; i.p.:
5 nmol), whereas control mice were treated either i.c.v.-aCSF or
i.p.-PBS. After injection, mice were individually put in metabolic
cages provided with preweighted amount of chow. Cumulative
food intakes were measured at specific time points after injection.
Immunohistochemistry
Immunohistochemical staining was performed on paraffin-
embedded brain sections (7 mm). Briefly, sections were deparaffi-
nizated, rehydrated, and permeabilized in PBS-BT (phosphate-
buffered saline supplemented with 2% bovine serum albumin and
0.5% Triton X-100). Thereafter, endogenous peroxidase activity
was blocked by treatment with 3% hydrogen peroxide, followed by
microwave antigen retrieval. After blocking with normal serum,
sections were incubated with primary antibody, and immunore-
active signals were detected using either the Vectastain ABC Elite
kit (PK-6101, Vector Laboratories, Burlingame, CA), or proceed
to fluorescence secondary antibody incubation for visualization
using Zeiss LSM 510 Meta computerized image analysis system.
The number of positive immunoreactive cells was counted from
both sides of the brain. The sum of the number of Fos-expressing
cells on both sides was calculated in each animal and used for
statistical analysis. Primary antibodies used were: 1:500 rabbit
anti-Fos Ab (Santa Cruz Biotechnology, Santa Cruz, CA) and
1:5000 goat anti-POMC Ab (Abcam, Cambridge, MA; Raised
against synthetic peptide C-NAIIKNAYKKGE, corresponding to
C terminal amino acids 256–267 of Human POMC). Secondary
antibodies used were: 1:300 Alexa Fluor 488 donkey anti-rabbit
IgG (Invitrogen, Carlsbad, CA) and 1:300 Alexa Fluor 555 donkey
anti-goat IgG (Invitrogen).
Statistical Analysis
All data are shown as means6 SEM and were analyzed by two-
way ANOVA with Bonferroni posttests using the computer
software PRISM (version 4.0; GraphPad).
Results
Peripheral SCT Decrease Food Intake via the Vagal
Afferent Nerve
We have previously demonstrated that both centrally injected
and peripherally administered SCT decreases food intake in mice,
and that the anorectic effect of centrally injected SCT is mediated
by the melanocortin system [16]. To investigate the pathway
through which peripherally injected SCT reduces food intake, the
effect of vagotomy on SCT-injected and control mice was studied.
A single i.p. administration of SCT (5 nmol) was shown to
significantly decrease food intake in sham-operated mice, but this
inhibitory effect on food intake was abolished in vagotomized mice
(Figure 1A). Since the subdiaphragmatic vagus is composed of a
number of branches, including the thick myelinated fibers, which
carry information mainly from the mechanoreceptors of the heart
and blood vessels [19], and a number of efferent and afferent
signals to and from a variety of abdominal organs, a specific
afferent neurotoxin, capsaicin, that kills only the unmyelinated
fibers, was used to further characterize if vagal afferent is involved
in the inhibition of food intake by SCT. Vehicle-treated mice
exhibited significant suppression of food intake after i.p. SCT
(5 nmol); whereas in capsaicin-treated mice, i.p. SCT failed to
suppress feeding (Figure 1B). This suggested that unmyelinated
fibers in the vagus nerve are responsible for carrying the signals
from i.p.-injected SCT to the higher center. Furthermore, as
vagotomy and capsaicin treatment were only effective in
abolishing the effect of peripherally administered SCT but not
centrally injected SCT (Figure 1C, 1D), therefore, these data
suggest that the vagal afferent is essential in mediating the
anorectic action induced by peripherally SCT.
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Peripheral SCT Activates POMC Neurons in the Arc via
the Vagal Afferent Nerve
We have previously shown that peripherally injected SCT
elevates POMC and Fos expression in POMC neurons in the Arc
[16], suggesting peripheral SCT modulates food intake in part via
the POMC neurons. To study if this signal is sent via the vagus
nerve to Arc, vagotomy and capsaicin treatment were again used.
In POMC neurons of sham-operated mice, i.p.-SCT could
consistently induce Fos expression, whereas in both capsaicin-
treated and vagotomized mice, i.p.-SCT-induced Fos expression
in POMC neurons was reduced (Figure 2), suggesting that SCT
signals its satiety effects to the higher centre through the vagus
nerve.
Peripheral SCT Causes Neuronal Activation in the
Brainstem
The brainstem and the hypothalamus are reciprocally connect-
ed. Within the brainstem, the dorsal vagal complex (DVC),
consisting of the area postrema (AP), NTS, and the dorsal motor
nucleus of the vagus nerve (DMV), is crucial for interpretating and
relaying of peripheral signals including the vagal afferents to the
hypothalamus. To determine if the anorectic effect of peripheral
SCT is sent via the brainstem to the Arc, Fos expression, a marker
for neuronal activation, was monitored by immunohistochemical
examination after peripheral injection of SCT. We found that i.p.-
SCT could increase the number of Fos-positive cells in the AP,
NTS and DMV, whereas subdiaphragmatic vagotomy significant-
ly decreased the number of i.p.-SCT-induced Fos positive cells in
these areas (Figure 3A). This data is consistent with the previous
Figure 1. Effect of vagotomy (A,C) and capsaicin treatment (B,D) on i.p. 5 nmol SCT (A,B)- and i.c.v. 0.15 nmol SCT (C,D)-induced
food intake. Food intake amount were represented as cumulative value at different time points (1, 2, 4, 6, and 8 h) after SCT treatment. Data are
expressed as the means 6 SEM (n= 10/group). * p,0.05, ** p,0.01 compared with the sham-operated mice injected with i.p.-PBS/i.c.v.-aCSF. N
p,0.05, NN p,0.01 compared with surgical/chemical-treated mice injected with i.p.-PBS/i.c.v.-aCSF.
doi:10.1371/journal.pone.0064859.g001
Vagal Input Mediates Anorectic Effects of Secretin
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e64859
Figure 2. The effect of vagotomy, capsaicin treatment, and sham operation on SCT-induced Fos expression in POMC neurons.
doi:10.1371/journal.pone.0064859.g002
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finding that showed a dose-dependent increase in the number of
Fos-positive neurons in AP, NTS, and DMV [18], and indicated
that the vagus nerve is responsible for relaying the peripheral SCT
anorectic signal to the central nervous system via the brainstem.
To further substantiate the role of vagus pathway in mediating
i.p.-SCT effect on food intake, midbrain transection was
performed at a site rostral to the NTS to cause lesion in areas
containing the ascending efferents of the NTS. Our data showed
that transection of all ascending NTS projection could block the
ability of i.p.-SCT in reducing food intake (Figure 3B), supporting
that neural pathway ascending from the NTS play a role in the
transmission of SCT-induced anorectic signals to the hypothala-
mus, and that the route for i.p.-SCT induced anorectic behaviour
is gut vagus nerve NTS forebrain regions.
Discussion
The hormone SCT is released from intestinal enteroendocrine
S-cells after a meal, and its action in regulating pancreatic exocrine
secretion of water and biocarbonate, gastric acid secretion, and
gastric motility are well studied. Recently, our laboratory has
demonstrated that the peptide, when injected peripherally, could
also act as a satiety signal, decreasing food intake and altering the
expression of neuropeptides within the Arc [16]. In this study, we
further substantiate this finding and demonstrate the role of the
vagus nerve, particularly the non-myelinated fibers in the afferent
pathway, in mediating SCT’s effect on appetite. We found that
vagus nerve pathway is specifically employed by peripheral SCT,
but not centrally expressing SCT in regulating the feeding
behavior, as bilateral subdiaphragmatic vagotomy and capsaicin
treatment could only block the anorectic effects, as well as the
induced activation of POMC neurons in the Arc, triggered by i.p.-
SCT, but not i.c.v.-SCT. This finding clearly indicates that vagal
afferents are required for the action of circulating SCT.
Supporting this notion, SCT was shown to regulate gastric
relaxation [20], pancreatic secretion [21], as well as gastric acid
secretion [22] via the vagal afferent pathways originating in the
gastrointestinal mucosa. In addition, its receptor was previously
found to be expressed in the nodose ganglion of the vagus nerve
[18], and is axonally transported and accumulated in vagus nerve
fibers that terminate in the forestomach [23,24]. All these findings
provide anatomical evidence to support the functional role of SCT
in modulating appetite via the vagus nerves.
The pathways through which vagus nerves transmit SCT-
induced pancreatic exocrine secretion of fluid and bicarbonate,
gastric acid secretion, and gastric motility have previously been
suggested [20–22]. The effect was believed to be mediated by
NTS, a region within the brainstem integrating and relaying
information between the gut via the vagus nerve and other second
order neurons in the higher centre, including Arc, dorsomedial
and PVN [25] in the hypothalamus. Previous report suggested that
i.p.-SCT could induce Fos expression in the NTS and Arc through
the vagal pathway [18], and depolarize NTS neurons through
activation of a nonselective cationic conductance [26]. Similarly,
we now show a direct neuronal activating effect of i.p.-SCT on AP,
NTS and DMV in sham-operated mice but not in vagotomised
and capsaicin-treated mice. In addition, we also show that bilateral
midbrain transection could block i.p.-SCT-induced feeding
reduction. Since we have previously shown the anorectic action
of SCT via its effects on hypothalamic arcuate POMC neurons
[16], we propose that SCT released from the gut may act in a
paracrine fashion to activate SCTR in the vagal afferents,
signalling to the NTS, which in turn communicates with the
hypothalamus so as to modify appetite.
Apart from SCT, many other gut peptides have also been
shown to influence appetite via the vagal afferent pathway.
Including in the list are glucagon-like peptide 1 (GLP-1) [27],
peptide YY [28], amylin [29], and cholecystokinin (CCK) [30,31].
However, among these, GLP-1, CCK, and amylin all exemplify
gut peptide that could inhibit appetite via vagal and non-vagal
routes of communication with the brain [29,32]. It was shown that
reduction of food intake by i.p. injection, but not intravenous
injection, of GLP-1 and CCK is abolished by capsaicin treatment
or vagotomy [27,32], whereas in the case of amylin, visceral
afferents do not even seem to be involved in mediating the
anorectic effect of i.p. administered amylin [29]. One possibility is
that these peptides may have access to specific brain sites,
including AP, where the BBB is incomplete as in the case of
amylin. The other possibility is that these peptides could directly
diffuse across the BBB as in the case of GLP-1 [33]. SCT have also
been shown to have the ability to cross the blood-brain barrier
[17]. However, as vagotomy and capsaicin treatment can both
completely attenuate its anorectic effect, as well as its neuronal
activating effect in AP, NTS and DMV, when i.p. was used as a
route for SCT administration, therefore, modulation of food
intake by i.p. SCT can be considered to neither involve a direct
binding of the peptide to its receptor in specific brain regions lying
outside the BBB, nor a direct diffusion of the peptide across the
BBB. In conclusion, we believed that the satiety signal of
peripheral SCT released from the gastrointestinal tract is sent
via the vagus nerves to the brainstem and subsequently Arc, where
it controls central expression of other regulatory peptides to
regulate food intake.
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